Therapeutics

After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO

3 monthes ago   |   By Xconomy

It's been a busy week for Repare Therapeutics. On Tuesday, the cancer drug developer struck up an alliance with Bristol Myers Squibb that pays $65 million now and as much as $3 billion later, depending on the progress made in coming years. On Friday, Repare filed for an IPO that could bring in more capital much sooner. Repare doesn't yet have any drugs in clinical testing, but now that its approach to cancer has drawn the attention of a big pharmaceutical company, it's betting it can also draw interest from a broader swath of investors. Montreal-based Repare, which...
Read more ...

 

Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs

Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs

3 monthes ago   |   By Xconomy

Forma Therapeutics has developed a pipeline of small molecules aimed at rare blood disorders and cancers, but it aims to advance two-investigational treatments for sickle cell disease and for advanced prostate cancer-and find partners for the rest of them. Now the Watertown, MA-based company is considering tapping the public markets to add enough funds to move one of its pair of core drug candidates further along in the clinic and to start human tests of the other. Forma set a preliminary $150 million goal for its IPO and says it plans to apply for a Nasdaq listing under the stock symbol...
Read more ...

 


Search by Tags

   Therapeutics      Drug      Clinical      Cancer      Pharmaceuticals      Pharmaceutical      Drugs      Boston      Boston blog main      Boston top stories      Boulder      Denver blog main      Europe blog main      National blog main      New York blog main      San Francisco blog main      Agnel Sfeir      Bayer      Biotech      Bristol-myers Squibb      Cancer Drugs      Clinical trials      CRISPR      Cyteir Therapeutics      Daniel Durocher      Financing      Frank Sicheri      Ideaya Biosciences      IPO      Life Sciences      Lunenfeld-Tanenbaum Research Institute      Merck Serono      Mount Sinai Hospital      MPM Capital      Nasdaq      NYU Langone Medical Center      Oncology      Orbimed      PARP inhibitor      PARP inhibitors      Repare Therapeutics      Synthetic lethality      Tango Therapeutics      Venture Capital      Versant Ventures      NASDAQ      Applied      Baker Bros. Advisors      Biomedical Sciences Investment Fund      Boehringer Ingelheim      Cancer      Celgene      CellCentric      Constellation Pharmaceuticals      Cormorant Asset Management      David Cook      Eli Lilly      FORMA Therapeutics      Frank Lee      Genentech      KRAS      Novartis      Patrick Kelly      RA Capital      Seres Therapeutics      Takeda Pharmaceutical  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That Produce Matter From Light

This image shows a reconstruction of a particle event at CERN's ATLAS detector that produced W bosons from photons, which are particles of light. Researchers at the U.S... Read more ...

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

An Alzheimer's disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have... Read more ...

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

The key to Athira Pharma's approach to Alzheimer's disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What's needed to begin the... Read more ...

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently... Read more ...

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Even in the field of genomics where new breakthroughs occur every few months, completion of the first-ever fully sequenced human autosome is a momentous achievement. Highly... Read more ...

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years... Read more ...

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET... Read more ...

Knockoff Boosted Tree for Model-Free Variable Selection

AbstractMotivationThe recently proposed knockoff filter is a general framework for controlling the false discovery rate when performing variable selection. This powerful new... Read more ...

IsoResolve: Predicting Splice Isoform Functions by Integrating Gene and...

AbstractMotivationHigh resolution annotation of gene functions is a central goal in functional genomics. A single gene may produce multiple isoforms with different functions... Read more ...

Bedtk: Finding Interval Overlap with Implicit Interval Tree

AbstractSummaryWe present bedtk, a new toolkit for manipulating genomic intervals in the BED format. It supports sorting, merging, intersection, subtraction and the calculation... Read more ...